CervoMed vs Kiora Pharmaceuticals
CRVO and KPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRVO and KPRX compare
CervoMed is the larger company, worth 5.5 times as much as Kiora Pharmaceuticals ($22.7M against $4.1M).
Kiora Pharmaceuticals scores higher on the StockData Score (7 against 5 for CervoMed), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRVO | KPRX |
|---|---|---|
| Size and price | ||
| Market cap | $22.7M | $4.1M |
| Share price | $1.50 | $0.930 |
| Change, 1 year | −80.5% | −56.9% |
| Change, 5 years | −94.9% | −99.8% |
| Beta (5Y) | 3.41 | 1.65 |
| Employees | 15 | 3,500 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 68.5× | – |
| P/B | 1.0× | 0.2× (better) |
| FCF yield | – | −209% |
| Growth | ||
| Revenue growth (TTM) | −95.7% | – |
| Profitability | ||
| Operating margin | −9407% | – |
| Net margin | −9161% | – |
| Return on equity | −108% | −56.4% (better) |
| Return on invested capital | – | −1374% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | – | 8.97 |
| Altman Z-score | −5.50 (better) | −9.82 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 11.6% | 25.0% |
| Held by insiders | 36.9% | 3.0% |
| Insider net buying, 12 months | $3.0M | – |
| Short interest, % of float | 12.7% | – |
Go deeper
- CRVO stock overview
- CRVO income statement
- CRVO valuation and score
- KPRX stock overview
- KPRX income statement
- KPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.